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Abstract
Introduction: Obstructive jaundice as a result of bile duct tumour thrombus (BDTT) is an unusual clinical
entity and an uncommon presenting feature of hepatocellular carcinoma (HCC). This study evaluates the
outcome of hepatectomy for HCC with obstructive jaundice as a result of BDTT in non-cirrhotic livers.
Methods: Between 1997 and 2012, out of 426 patients with HCC in non-cirrhotic livers, 39 patients with
BDTT (Group I n = 39), who underwent a hepatectomy, were analysed and compared with the non-BDTT
group (Group II n = 387).
Results: The demographic profile and biochemical parameters between Group I and Group II were
compared; apart from the presence of jaundice at presentation and an elevated serum bilirubin, there
were no significant differences. Post-operative morbidity and mortality were 11 (28.2%) and 2 (5.1%),
respectively, in Group I. There were no differences between the groups with regards to the operative
variables and short-term outcomes. The 1-, 3- and 5-year survival rates in Group I were 82%, 48% and
10%, respectively, with a median survival of 28.6 months and were significantly poorer than Group II
(90%, 55% and 38%, respectively, with a median survival of 39.2 months).
Conclusion: The mere presence of BDTT in HCC does not indicate an advanced or inoperable lesion.
When technically feasible, a formal hepatic resection is the preferred first-line treatment option in these
patients.
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Introduction
Obstructive jaundice is an uncommon presenting feature of hepa-
tocellular carcinoma (HCC). The incidence of obstructive jaun-
dice in HCC is in the range of 1% to 12%, with a tumour
thrombus in the bile duct (BDTT) being one of the causes.1–3
These patients exhibit clinicopathological features which differ
from those with parenchymal cholestasis owing to extensive
tumour infiltration or advanced cirrhosis.4,5 Even although the
prognosis in this type of HCC is poor, it is much better than those
with jaundice caused by hepatic insufficiency.4,5 Identification of
this group of patients is imperative, because surgical treatment
may be beneficial. There is a paucity of studies regarding BDTT in
HCC, especially with respect to the outcome of hepatectomy and
its impact on prognosis. In this study, we aimed to evaluate the
outcome of hepatectomy for HCC in patients with obstructive
jaundice as a result of BDTT in a non-cirrhotic liver and compare
its morbidity, mortality and long-term prognosis with those who
underwent a resection without BDTT.
Materials and methods
From January 1997 to December 2012, 426 patients with a non-
fibrolamellar type of HCC in non-cirrhotic livers underwent liver
resections at the Institute of Surgical Gastroenterology and Liver
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Transplantation, Stanley Medical College Hospital, Chennai,
India. Among them, 39 patients were diagnosed to have patho-
logically confirmed (post-operative) BDTT (Group I). These
patients were compared with the remaining 387 patients without
BDTT (Group II). Their demographic, clinicopathological and
investigative (biochemical and radiological) data were noted.
Hepatocellular carcinoma with BDTT was classified according to
the location of BDTT, as proposed by Ueda et al. (Type 1: involv-
ing the second order intrahepatic duct, Type 2: involving the first-
order intrahepatic duct, Type 3a: extending to the hepatic
confluence, Type 3b: implanted tumour growing in the common
hepatic duct (CHD) and Type 4: dislodged BDTT within the
CHD) (Fig. 1).6
Pre-operative workup included liver function tests, viral screen
and imaging in the form of abdominal ultrasonography, and
abdominal computed tomography (CT) (Fig. 2a–c). Magnetic
resonance cholangiopancreatography, when available, was used to
evaluate the extent of a BDTT (Fig. 2d). Operative procedures
were based on the general condition, tumour status, pre-operative
liver function tests, pre-operative diagnosis of the location of the
primary tumours, extension of BDTT and the future remnant
liver parenchyma. Pre-operative biliary drainage in the form of
percutaneous transhepatic biliary drainage was performed selec-
tively when the patient’s serum bilirubin was more than 5 mg/dl
or if the patient developed cholangitis. Anatomical resection was
done for the primary liver tumour. For a free-floating thrombus in
the bile duct, a choledochotomy was done and the tumour was
extricated. (Fig. 3) In cases of an invaded bile duct, it was resected
with the entire tumour, and biliary-enteric anastomosis was per-
formed. The specimen was labelled and sent for histopathological
examination. Tumour size, number, surgical margin, classification
of thrombus and its size were noted. The operation time was
defined as the time period from incision of the skin to closure of
the wound. Post-operative morbidity included all the complica-
tions related to the hepatic surgery. Peri-operative mortality was
defined as either within 30 days of surgery or occurring in hospi-
tal. After discharge, patients were followed-up on a 3-monthly
basis with alpha fetoprotein (AFP) and ultrasound or CT every 3
months for the first 2 years, beyond which the patient was
followed-up on a 6-monthly basis.
Statistical analysis
Data were expressed as the mean ± SD for numerical variables or
percentages for nominal variables. Mann-Whitney U test or t-tests
were used to compare numerical variables, and the Chi-Square
test or Fisher’s exact test was carried out to compare nominal
variables. Overall survival rates were estimated using the Kaplan–
Meier method and compared using the log-rank test. Statistical
analysis was performed using the SPSS software (version 16.0;
SPSS, Inc., Chicago, IL, USA). P < 0.05 was considered statistically
significant.
Results
The demographic profile of the patients in BDTT and non-BDTT
groups were compared with regards to their age, gender, viral
marker status, Child–Pugh status and jaundice at presentation
(Table 1). In total, 18 patients with BDTT (46.1%) presented with
jaundice on admission, which was significantly higher than the
non-BDTT group (1.5%). In the non-BDTT group, jaundice was
as a result of the presence of a centrally located tumour with direct
compression over the biliary radicals or haemobilia. There were
no other significant differences between the two groups. On com-
parison of biochemical parameters between the two groups
(Table 2), the serum bilirubin levels were significantly higher in
the BDTT group. There were no other differences in biochemical
parameters noted between the groups.
Sixteen patients underwent a right hepatectomy with a tumour
thrombectomy via a choledochotomy. An extended right hepate-
ctomy with extra hepatic bile duct excision was the next most
Figure 1 UEDA classification of bile duct thrombi6
HPB 2015, 17, 508–513 ª 2015 International Hepato-Pancreato-Biliary Association
HPB 509
common procedure (n = 10). A left hepatectomy was performed in
9 patients whereas 2 patients each underwent an extended left
hepatectomy and left lateral segmentectomy (Table 3). There were
no differences in the average blood loss and operative times
between the two groups. (Table 4)
The tumour characteristics (number, size, tumour thrombus
length and Ueda classification based on pathology) of the resected
specimen are summarized in Table 5. Post-operative morbidity in
the BDTT group was 28.2% (n = 11) which included bile leak in
four patients. Two patients died as a result of post-hepatectomy
liver failure (mortality 5.1%). There was no significant difference
in the morbidity, length of hospital stay, mortality and margin
positivity between the groups (Table 6). The median follow-up for
the patients was 64 months (12–144). The median survival and
overall 1-, 3- and 5-year survival were significantly poorer in the
BDTT group (Table 7). Kaplan–Meier curves for overall survival
of the two groups were plotted, and are shown in Fig. 4.
Discussion
Since its first description in 1949, icteric hepatomas have
remained an enigmatic subset of HCC.7 Their diagnosis, ideal
management and outcomes after a hepatectomy have been an area
of speculation and controversy. The incidence of BDTT in HCC
varies from 0.8% to 12.5%.2,3 In our series, the incidence of BDTT
among non-cirrhotic livers with HCC was 9.1%. The outcome in
patients who receive palliative treatment is uniformly dismal, with
a mean survival time of less than 5 months.8–11 For HCC patients
with BDTT, surgical resection is the only option for curative treat-
ment, increasing the chance of survival.
As HCC with BDTT is often accompanied by obstructive jaun-
dice, it is difficult to assess the hepatic functional reserve before
determining treatment. However, liver function does recover if
jaundice is relieved by biliary decompression. This permits
an assessment of hepatic functional reserve and safe liver
resection.1,5,12 Theories regarding the pathogenesis of BDTT
Figure 2 Pre-operative imaging of bile duct tumour thombus (BDTT) in hepatocellular carcinoma (HCC). (a) Ultrasonography of BDTT (arrow).
(b) Colour Doppler of BDTT (arrow). (c) Computed tomography (CT) showing BDTT. (d) Magnetic resonance cholangiopancreatography
showing BDTT
Figure 3 Intra-operative bile duct tumour thombus (BDTT) within the
lumen of the common bile duct
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include a rupture of the HCC into the common bile duct, or an
invasion of the intrahepatic bile duct system by the tumour. The
presence of concurrent haemobilia can accelerate the obstructive
jaundice, causing patients to become icteric within a few days.1,5,13
BDTT in the proximal bile duct system may be expanding in
nature and loosely attached to the bile duct epithelium, hence
enabling a tumour thrombectomy through choledochotomy,
avoiding the need for resection of the bile duct.5,14–16 In our
patients, pre-operative biliary decompression was done on a
selective basis, percutaneous transhepatic biliary drainage
(PTBD) was the modality of choice and there were no PTBD-
related complications.
Table 1 Demographic profile
BDTT
n = 39
Non BDTT
n = 387
P value
Age (years) 52.1 ± 10.9 50.9 ± 18.8 NS
Males/Females
n
28/11 278/109 NS
HBV positive
n (%)
7 (17.9%) 61 (15.7%) NS
HCV positive
n (%)
2 (5.1%) 6 (1.5%) NS
Jaundice at presentation n (%) 18 (46.1%) 5 (1.3%) P < 0.05
Child–Pugh Class A/B (%) 27 (69.3)/12 (30.7) 271 (70.1)/116 (28.9) NS
HBV, hepatitis B virus; HBC, hepatitis C virus.
Table 2 Biochemical parameters
BDTT
n = 39
Non BDTT
n = 387
P-value
S. bilirubin (mg/dl) 6.1 ± 5.1 1.2 ± 0.7 P < 0.05
S. AST (IU/l) 88.9 ± 39 69.2 ± 31 NS
S. alkaline phosphatase (IU/l) 522 ± 248 284 ± 166 NS
S. albumin (g/dl) 4.1 ± 3.1 4.0 ± 1.4 NS
AFP (> 400 ng/ml) 28 (71.7%) 281 (72.6%) NS
BDTT, bile duct tumour thombus; AST, aspartate aminotransferase; AFP,
alpha fetoprotein; NS, not significant.
Table 3 Operative procedure
Operative procedure n = 39
Right hepatectomy with thrombectomy through
choledochotomy and T tube drainage
16
Extended right hepatectomy with extra hepatic bile duct
excision
10
Left hepatectomy 9
Extended left hepatectomy 2
Left Lateral Segmentectomy 2
Table 4 Operative variables
BDTT
n = 39
Non BDTT
n = 387
P-value
Duration of surgery (min) 480 ± 45 465 ± 55 NS
Blood loss (ml) 390 ± 45 375 ± 65 NS
BDTT, bile duct tumour thombus; NS, not significant.
Table 5 Tumour characteristics
Tumour
Number 2 ± 1
Size (cm) 5.6 ± 3.2
Thrombus length (cm) 5.5 ± 2.5
UEDA classification
I 4
II 8
IIIa 17
IIIb 2
IV 8
Table 6 Short-term outcomes
BDTT
n = 39
Non BDTT
n = 387
P value
Morbidity (%) 11 (28.2) 105 (27.1) NS
Length of hospital stay (Days) 17.6 ± 6.0 16.1 ± 5.1 NS
Mortality (%) 2 (5.1) 15 (3.9) NS
Positive Margin (%) 3 (7.7) 27 (6.9) NS
BDTT, bile duct tumour thombus; NS, not significant.
Table 7 Long-term survival
Survival BDTT
n = 39
Non BDTT
n = 387
P-value
Median survival (months) 28.6 39.2 P < 0.05
Overall survival (%)
1 year 82 90 P < 0.05
3 years 48 55 P < 0.05
5 years 10 38 P < 0.05
BDTT, bile duct tumour thombus; NS, not significant.
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Venous invasion is a well-established prognostic indicator in
HCC.5,15,16 In contrast, whether BDTT has a significant impact on
the prognosis of HCC remains controversial, and there is no con-
sensus regarding its efficacy as an indicator of poor prognosis.
Shiomi et al. and Satoh et al. found no significant differences in
survival between patients with BDTT and those without BDTT.1,13
On the other hand, recent studies including ours, have observed
significantly poorer survival outcomes in patients with BDTT
after surgery.2,10–12,17
The results of univariate survival analysis from a recent Korean
multicentre study showed that the maximal tumour size, bile duct
resection and surgical curability were significant risk factors for
survival, and surgical curability was a significant risk factor for
recurrence. However, multivariate analysis did not reveal any
independent risk factors.5 Experience with liver transplantation in
patients with BDTT is limited. Reports from Korea have suggested
liver transplantation may be an effective treatment in cirrhotic
patients with HCC-BDTT.18
Conclusion
HCC with BDTT, particularly with obstructive jaundice as the
main presenting clinical feature, is uncommon. The prognosis of
this type of HCC is generally dismal, but is better than those who
have not undergone a resection. Jaundice is not necessarily a har-
binger of advanced disease and a contraindication for surgery.
When appropriately selected and carried out safely, surgery can
result in long-term survival. A deeper understanding and active
attitude to treatment of this type of disease are the keys to further
improving survival of these patients. When technically feasible,
curative surgery is recommended as the first-line treatment for
icteric hepatomas.
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